Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Disappointing
View:
Post by Viking2233 on Sep 22, 2023 9:11am

Disappointing

Generally speaking companies release news on Fridays because it is not positive, now todays news release is not negative but will have zero impact.

This management team likes to promote the fact that they dont release fluff, todays news is nothing new to the markets. The markets know from previous release that they are starting a FDA approved phase 2 trial for AKI that will take place in Turkey, Canada and USA in fall of 2023.

This is simply a repeat, fluff that will have zero impact.

I suspect this was generated so the algorithms pick up on it.

They could have added that the new trial is fully funded with capital received from Government grants but they did not even mention that.

I was really hoping the next news release might be release of third party peer review or first patient dosed but they dont even have approval from Turkish authorities to commence the trial.

Management continues to drop the ball! The only saving grace is the solid science.
Comment by TechTitan on Sep 22, 2023 10:24am
They submit the application to the Turkish Minister almost 12 weeks after the FDA announcement..... lol wow! 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities